Effects of Valproate and Carbamazepine Monotherapy on Leukocyte Subsets and Neutrophil-Lymphocyte Ratio in Children

Sevim Şahin

  • Year : 2025
  • Vol : 41
  • Issue : 1
  •  Page : 12-18
ABSTRACT
Objective: Although the adverse effects of anti-seizure medications (ASMs), like leukopenia and neutropenia, are widely recognized, little is known about how they affect leukocyte subsets. Changes in leukocyte subsets are also used to assess the inflammation status during diseases. The neutrophil-to-lymphocyte ratio (NLR) is widely used for this purpose. This study aims to evaluate the effects of valproate (VPA) and carbamazepine (CBZ) monotherapy on leukocyte subsets and NLR and to determine the relationship of these effects with serum drug levels.
Material and Methods: The data of children with idiopathic epilepsy who began CBZ (n=25) or VPA monotherapy (n=62) and underwent complete blood count examinations before treatment and at 1–6 months (T1) and 9–18 months (T2) after treatment, with at least one concurrent serum ASM level, were collected retrospectively. The data included the number and percentages of leukocytes, neutrophils, lymphocytes, and monocytes, as well as simultaneously measured serum ASM levels. The relationships between serum ASM levels and variables were evaluated with 130 simultaneous measurements in the VPA and 30 in the CBZ groups.
Results: In the VPA group, when compared to baseline, neutrophil count and NLR decreased (p=0.026, p=0.038, respectively), and lymphocyte and monocyte percentages increased (p=0.015, p<0.001, respectively). There were no significant changes in the CBZ group. Serum VPA levels were positively correlated with monocyte counts (r=0.2, p=0.022). Serum CBZ levels were negatively correlated with neutrophil counts (r= -0.574, p=0.001) and NLR (r= -0.413, p=0.023).
Conclusion: VPA monotherapy significantly decreased NLR, supporting its anti-inflammatory effects. The negative correlation of serum CBZ levels with NLR suggested that CBZ may have a dose-related effect on NLR. Consideration of these results may be beneficial in choosing an appropriate ASM for patients with epilepsy.
Keywords: Carbamazepine, leukocyte subsets, neutrophil-lymphocyte ratio, valproate
Cite this Article As : Sahin S. Effects of Valproate and Carbamazepine Monotherapy on Leukocyte Subsets and Neutrophil-Lymphocyte Ratio in Children. Selcuk Med J 2025;41(1): 12-18

Download Citation: Endnote/Zotero/Mendeley (RIS) RIS File

Download Citation: BibTeX BibTeX File

Conflict of interest : The authors declare that they have no conflict of interest.
This article is published under the CC BY-NC 4.0 license.
Selcuk Medical Journal
2025, Vol. 41 (1)
ISSN: 1017-6616
E-ISSN: 2149-8059
Received : , Accepted : , Published Online :

References

  1. 1. Chou IC, Chang YT, Chin ZN, et al. Correlation between Epilepsy and Attention Deficit Hyperactivity Disorder: A Population-Based Cohort Study. PLoS One. 2013;8(3):e57926. doi: 10.1371/journal.pone.0057926.
  2. 2. Covan LD. The epidemiology of the epilepsies in children. Ment Retard Dev Disabil Res Rev.2002;8(3):171-81. doi: 10.1002/mrdd.10035.
  3. 3. Bachmann T, Bertheussen KH, Svalheim S, et al. Haematological side effects of antiepileptic drug treatment in patients with epilepsy. Acta Neurol Scand. 2011;124(7):23–7. doi: 10.1111/j.1600-0404.2011.01539.x.
  4. 4. Verrotti A, Scaparrotta A, Grosso S, et al. Anticonvulsant drugs and hematological disease. Neurol Sci. 2014;35(7):983–93. doi: 10.1007/s10072-014-1701-0.
  5. 5. Pick AM, Nystrom KK. Nonchemotherapy drug-ınduced neutropenia and agranulocytosis. J Pharm Pract. 2014;27(5):447–52. doi: 10.1177/0897190014546115.
  6. 6. Bartels M, van Solinge WW, den Breeijen HJ, et al. Valproic acid treatment ıs associated with altered leukocyte subset development. J Clin Psychopharmacol [Internet]. 2012;32(6):832–4. doi: 10.1097/JCP.0b013e318270e5e2.
  7. 7. Söğütlü Y, Altaş U. Predictive value of neutrophil–lymphocyte ratio and other ınflammation ındices in febrile seizures in children. J Clin Med. 2024;13(17). doi: 10.3390/jcm13175330.
  8. 8. Vezzani A. Brain ınflammation and seizures: Evolving concepts and new findings in the last 2 decades. Epilepsy Curr. 2020;20(6_suppl):40S-43S.doi: 10.1177/1535759720948900.
  9. 9. Guenther S, Bauer S, Hagge M, et al. Chronic valproate or levetiracetam treatment does not influence cytokine levels in humans. Seizure. 2014;23(8):666–9. doi:10.1016/j.seizure.2014.04.011.
  10. 10. Gilhus NE, Matre R. Carbamazepine effects on mononuclear blood cells in epileptic patients. Acta Neurol Scand. 1986;74(3):181–5.doi:10.1111/j.1600-0404.1986.tb07852.x.
  11. 11. Çağ İ, Altun Y, Altunışık E. Do antiepileptic drugs have any effect on Neutrophil / Lymphocyte and Platelet / Lymphocyte Ratio? Med Sci Discov. 2019;90(12):76–81. doi: 10.17546/msd.533504.
  12. 12. Hosseini S, Mofrad AME, Mokarian P, et al. Neutrophil to lymphocyte ratio in epilepsy: a systematic review. Mediators Inflamm. 2022;4973996. doi: 10.1155/2022/4973996.
  13. 13. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase ıs a target of valproic acid-mediated cellular differentiation. Cancer Res. 2004;64(3):1079–86.. doi: 10.1158/0008-5472.can-03-0799.
  14. 14. Soria-Castro R, Schcolnik-Cabrera A, Rodríguez-López G, et al. Exploring the drug repurposing versatility of valproic acid as a multifunctional regulator of innate and adaptive immune cells. J Immunol Res. 2019;(14):2019:9678098. doi: 10.1155/2019/9678098.
  15. 15. Collazos J, Domingo P, Fernández-Araujo N, et al. Exposure to valproic acid is associated with less pulmonary infiltrates and improvements in diverse clinical outcomes and laboratory parameters in patients hospitalized with COVID-19. PLoS One. 2022;17(1):e0262777. doi: 10.1371/journal.pone.0262777.
  16. 16. Hauser E, Seidl R, Freilinger M, et al. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Brain Dev. 1996;18(2):105–9.doi:10.1016/0387-7604(95)00139-5.
  17. 17. Maës J, Maleszewska M, Guillemin C, et al. Lymphoid-affiliated genes are associated with active histone modifications in human hematopoietic stem cells. Blood. 2008;112(7):2722–9. doi:10.1182/blood-2008-02-140806.
  18. 18. Stewart MD, Li J, Wong J. Relationship between histone h3 lysine 9 methylation, transcription repression, and heterochromatin protein 1 recruitment. Mol Cell Biol. 2005;25(7):2525–38. doi: 10.1128/MCB.25.7.2525-2538.2005.
  19. 19. Bartels M, Geest CR, Bierings M, et al. Histone deacetylase inhibition modulates cell fate decisions during myeloid differentiation. Haematologica. 2010;95(7):1052–60. doi:10.3324/haematol.2009.008870.
  20. 20. Cho GW, Kang BY, Kim KS, Kim SH. Effects of valproic acid on the expression of trophic factors in human bone marrow mesenchymal stromal cells. Neurosci Lett . 2012;526(2):100–5. doi:10.1016/j.neulet.2012.08.015.
  21. 21. Tao R, De Zoeten EF, Özkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med. 2007;13(11):1299–307. doi:10.1038/nm1652.
  22. 22. Asadi-Pooya AA, Ghetmiri E. Folic acid supplementation reduces the development of some blood cell abnormalities in children receiving carbamazepine. Epilepsy Behav. 2006;8(1):228–31. doi:10.1016/j.yebeh.2005.10.002.
  23. 23. El-Shimi OS, Farag AA, El-Rebigi AM, et al. Carbamazepine-ınduced hematological and ımmunological alterations in Egyptian children with ıdiopathic generalized seizures. J Child Sci. 2021;11(1):265–72. doi:10.1055/s-0041-1736156
  24. 24. Caldiroli E, De Ponti F, Cosentino M, et al. Carbamazepine affects neutrophil function through an action on peripheral benzodiazepine receptors. Immunopharmacol Immunotoxicol. 1997;19(3):367–82. doi: 10.3109/08923979709046982.
  25. 25. Mintzer DM, Billet SN, Chmielewski L. Drug-induced hematologic syndromes. Adv Hematol. 2009;2009:495863. doi: 10.1155/2009/495863.
  26. 26. Furst SM, Uetrecht JP. Carbamazepine metabolism to a reactive intermediate by the myeloperoxidase system of activated neutrophils. Biochem Pharmacol. 1993;45(6):1267–75. doi: 10.1016/0006-2952(93)90279-6.
  27. 27. Yılmazbaş P, Şenbil N. Hematological side effects of valproate used for the treatment of epilepsy. Nam Kem Med J. 2021;9(1):39–42. doı: 10.4274/ nkmj.galenos.2020.800497.
  28. 28. Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: A prospective monotherapy study. Epilepsia. 2008;49(3):438–45. doi:10.1111/j.1528-1167.2007.01429.x.
  29. 29. Seetharam MN, Pellock JM. Risk-benefit assessment of carbamazepine in children. Drug Saf. 1991;6(2):148–58. doi:10.2165/00002018-199106020-00005.
  30. 30. Silverstein FS, Boxer L, Johnston M V. Hematological Monitoring During Therapy with Carbamazepine in Children Familial Periodic Paralysis : Low Muscle Potassium Permeability or High Sodium Permeability ? 1982;1982–3.
  31. 31. Bonhomme-Faivre L, Forestier F, Auchère D, et al. Chronic administration of verapamil, ketoconazole and carbamazepine: Impact on immunological parameters. Int J Pharm. 2002;238(1–2):133–7. doi:10.1016/S0378-5173(02)00056-X.
  32. 32. DA Silverman, DJ Chapron. Lymphopenic effect of carbamazepine in a patient with chronic lymphocytic leukemia. Ann Pharmacother. 1995;29(9):865-7. doi: 10.1177/106002809502900906.
  33. 33. Li H, Yang Y, Hu M, et al. The correlation of temporal changes of neutrophil-lymphocyte ratio with seizure severity and the following seizure tendency in patients with epilepsy. Front Neurol. 2022;13:964923. doi: 10.3389/fneur.2022.964923.